1. Non-mammalian Animal Models Offer New Perspectives on the Treatment of TBI
- Author
-
Barry Ganetzky and David A. Wassarman
- Subjects
0301 basic medicine ,Animal Welfare (journal) ,business.industry ,Traumatic brain injury ,Rehabilitation ,Medicine (miscellaneous) ,Flexibility (personality) ,Physical Therapy, Sports Therapy and Rehabilitation ,Affect (psychology) ,medicine.disease ,Bioinformatics ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Drug development ,Homogeneous ,Medicine ,Orthopedics and Sports Medicine ,business ,Neuroscience ,030217 neurology & neurosurgery - Abstract
Patients who have sustained a traumatic brain injury (TBI) exhibit clinical symptoms of widely varying types and severities. In contrast, because of cost, experimental flexibility, and animal welfare, preclinical rodent models of TBI are designed to exhibit relatively homogeneous symptoms. This disconnect may explain why drugs developed using rodent models have universally failed in clinical studies. We suggest that drug development for TBI could benefit from preclinical studies using non-mammalian animals, where cost, experimental flexibility, and animal welfare are less of an issue and variables that affect clinical symptoms, including genotype, age, and environmental factors, can be more extensively investigated.
- Published
- 2016
- Full Text
- View/download PDF